Literature DB >> 27185785

Merozoite Antigens of Plasmodium falciparum Elicit Strain-Transcending Opsonizing Immunity.

Danika L Hill1,2, Danny W Wilson3,2,4, Natalia G Sampaio3,2, Emily M Eriksson3,2, Victoria Ryg-Cornejo3,2, G L Abby Harrison3,2, Alessandro D Uboldi3,2, Leanne J Robinson3,2,5, James G Beeson6,7, Peter Siba5, Alan F Cowman3,2, Diana S Hansen3,2, Ivo Mueller3,2,8, Louis Schofield3,2,9.   

Abstract

It is unclear whether naturally acquired immunity to Plasmodium falciparum results from the acquisition of antibodies to multiple, diverse antigens or to fewer, highly conserved antigens. Moreover, the specific antibody functions required for malaria immunity are unknown, and hence informative immunological assays are urgently needed to address these knowledge gaps and guide vaccine development. In this study, we investigated whether merozoite-opsonizing antibodies are associated with protection from malaria in a strain-specific or strain-transcending manner by using a novel field isolate and an immune plasma-matched cohort from Papua New Guinea with our validated assay of merozoite phagocytosis. Highly correlated opsonization responses were observed across the 15 parasite strains tested, as were strong associations with protection (composite phagocytosis score across all strains in children uninfected at baseline: hazard ratio of 0.15, 95% confidence interval of 0.04 to 0.63). Opsonizing antibodies had a strong strain-transcending component, and the opsonization of transgenic parasites deficient for MSP3, MSP6, MSPDBL1, or P. falciparum MSP1-19 (PfMSP1-19) was similar to that of wild-type parasites. We have provided the first evidence that merozoite opsonization is predominantly strain transcending, and the highly consistent associations with protection against diverse parasite strains strongly supports the use of merozoite opsonization as a correlate of immunity for field studies and vaccine trials. These results demonstrate that conserved domains within merozoite antigens targeted by opsonization generate strain-transcending immune responses and represent promising vaccine candidates.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27185785      PMCID: PMC4962632          DOI: 10.1128/IAI.00145-16

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Antibodies to the Plasmodium falciparum Proteins MSPDBL1 and MSPDBL2 Opsonize Merozoites, Inhibit Parasite Growth, and Predict Protection From Clinical Malaria.

Authors:  Chris Y H Chiu; Anthony N Hodder; Clara S Lin; Danika L Hill; Connie S N Li Wai Suen; Louis Schofield; Peter M Siba; Ivo Mueller; Alan F Cowman; Diana S Hansen
Journal:  J Infect Dis       Date:  2015-02-02       Impact factor: 5.226

2.  Metabolic properties of IgG subclasses in man.

Authors:  A Morell; W D Terry; T A Waldmann
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

3.  Duration of naturally acquired antibody responses to blood-stage Plasmodium falciparum is age dependent and antigen specific.

Authors:  Onome J Akpogheneta; Nancy O Duah; Kevin K A Tetteh; Samuel Dunyo; David E Lanar; Margaret Pinder; David J Conway
Journal:  Infect Immun       Date:  2008-01-22       Impact factor: 3.441

4.  Identification of a potent combination of key Plasmodium falciparum merozoite antigens that elicit strain-transcending parasite-neutralizing antibodies.

Authors:  Alok K Pandey; K Sony Reddy; Tajali Sahar; Sonal Gupta; Hina Singh; E Jyotheeswara Reddy; Mohd Asad; Faiza A Siddiqui; Pankaj Gupta; Bijender Singh; Kunal R More; Asif Mohmmed; Chetan E Chitnis; Virander S Chauhan; Deepak Gaur
Journal:  Infect Immun       Date:  2012-11-26       Impact factor: 3.441

5.  Quantifying the importance of MSP1-19 as a target of growth-inhibitory and protective antibodies against Plasmodium falciparum in humans.

Authors:  Danny W Wilson; Freya J I Fowkes; Paul R Gilson; Salenna R Elliott; Livingstone Tavul; Pascal Michon; Elija Dabod; Peter M Siba; Ivo Mueller; Brendan S Crabb; James G Beeson
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

6.  Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria.

Authors:  Faith Ha Osier; Gaoqian Feng; Michelle J Boyle; Christine Langer; Jingling Zhou; Jack S Richards; Fiona J McCallum; Linda Reiling; Anthony Jaworowski; Robin F Anders; Kevin Marsh; James G Beeson
Journal:  BMC Med       Date:  2014-07-01       Impact factor: 8.775

7.  Contrasting population structures of the genes encoding ten leading vaccine-candidate antigens of the human malaria parasite, Plasmodium falciparum.

Authors:  Alyssa E Barry; Lee Schultz; Caroline O Buckee; John C Reeder
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

8.  The importance of human FcgammaRI in mediating protection to malaria.

Authors:  Richard S McIntosh; Jianguo Shi; Richard M Jennings; Jonathan C Chappel; Tania F de Koning-Ward; Tim Smith; Judith Green; Marjolein van Egmond; Jeanette H W Leusen; Maria Lazarou; Jan van de Winkel; Tarran S Jones; Brendan S Crabb; Anthony A Holder; Richard J Pleass
Journal:  PLoS Pathog       Date:  2007-05-18       Impact factor: 6.823

9.  High yield purification of Plasmodium falciparum merozoites for use in opsonizing antibody assays.

Authors:  Danika L Hill; Emily M Eriksson; Louis Schofield
Journal:  J Vis Exp       Date:  2014-07-17       Impact factor: 1.355

10.  IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life.

Authors:  Samson M Kinyanjui; David J Conway; David E Lanar; Kevin Marsh
Journal:  Malar J       Date:  2007-06-28       Impact factor: 2.979

View more
  19 in total

1.  Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial.

Authors:  Antje Blank; Kristin Fürle; Anja Jäschke; Michael Lanzer; Walter E Haefeli; Hermann Bujard; Gerd Mikus; Monika Lehmann; Johannes Hüsing; Kirsten Heiss; Thomas Giese; Darrick Carter; Ernst Böhnlein
Journal:  NPJ Vaccines       Date:  2020-01-31       Impact factor: 7.344

2.  Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria.

Authors:  Anja Jäschke; Boubacar Coulibaly; Edmond J Remarque; Hermann Bujard; Christian Epp
Journal:  Clin Vaccine Immunol       Date:  2017-11-06

3.  Age-dependent changes in circulating Tfh cells influence development of functional malaria antibodies in children.

Authors:  Jo-Anne Chan; Jessica R Loughland; Lauren de la Parte; Satomi Okano; Isaac Ssewanyana; Mayimuna Nalubega; Felistas Nankya; Kenneth Musinguzi; John Rek; Emmanuel Arinaitwe; Peta Tipping; Peter Bourke; Dean Andrew; Nicholas Dooley; Arya SheelaNair; Bruce D Wines; P Mark Hogarth; James G Beeson; Bryan Greenhouse; Grant Dorsey; Moses Kamya; Gunter Hartel; Gabriela Minigo; Margaret Feeney; Prasanna Jagannathan; Michelle J Boyle
Journal:  Nat Commun       Date:  2022-07-18       Impact factor: 17.694

4.  Plasmodium falciparum MSP3 Exists in a Complex on the Merozoite Surface and Generates Antibody Response during Natural Infection.

Authors:  Arunaditya Deshmukh; Bishwanath Kumar Chourasia; Sonali Mehrotra; Ikhlaq Hussain Kana; Gourab Paul; Ashutosh Panda; Inderjeet Kaur; Susheel Kumar Singh; Sumit Rathore; Aparup Das; Priya Gupta; Md Kalamuddin; S K Gakhar; Asif Mohmmed; Michael Theisen; Pawan Malhotra
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

5.  Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG1-4, IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies.

Authors:  Itziar Ubillos; Alfons Jiménez; Marta Vidal; Paul W Bowyer; Deepak Gaur; Sheetij Dutta; Benoit Gamain; Ross Coppel; Virander Chauhan; David Lanar; Chetan Chitnis; Evelina Angov; James Beeson; David Cavanagh; Joseph J Campo; Ruth Aguilar; Carlota Dobaño
Journal:  Malar J       Date:  2018-06-01       Impact factor: 2.979

6.  Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development.

Authors:  Camila Tenorio França; Michael T White; Wen-Qiang He; Jessica B Hostetler; Jessica Brewster; Gabriel Frato; Indu Malhotra; Jakub Gruszczyk; Christele Huon; Enmoore Lin; Benson Kiniboro; Anjali Yadava; Peter Siba; Mary R Galinski; Julie Healer; Chetan Chitnis; Alan F Cowman; Eizo Takashima; Takafumi Tsuboi; Wai-Hong Tham; Rick M Fairhurst; Julian C Rayner; Christopher L King; Ivo Mueller
Journal:  Elife       Date:  2017-09-26       Impact factor: 8.140

7.  Cellular dissection of malaria parasite invasion of human erythrocytes using viable Plasmodium knowlesi merozoites.

Authors:  Oliver Lyth; Gema Vizcay-Barrena; Katherine E Wright; Silvia Haase; Franziska Mohring; Adrian Najer; Isabelle G Henshall; George W Ashdown; Lawrence H Bannister; Damien R Drew; James G Beeson; Roland A Fleck; Robert W Moon; Danny W Wilson; Jake Baum
Journal:  Sci Rep       Date:  2018-07-05       Impact factor: 4.379

Review 8.  Novel Strategies for Malaria Vaccine Design.

Authors:  Augustina Frimpong; Kwadwo Asamoah Kusi; Michael Fokuo Ofori; Wilfred Ndifon
Journal:  Front Immunol       Date:  2018-11-29       Impact factor: 7.561

9.  Antibody immunoglobulin G1 and immunoglobulin G2a responses against some cystic fluid proteins of Cysticercus bovis in Balb/c mice.

Authors:  I Nyoman Mantik Astawa; Ida Bagus Made Oka; I Made Dwinata
Journal:  Vet World       Date:  2018-11-30

10.  In vitro invasion inhibition assay using antibodies against Plasmodium knowlesi Duffy binding protein alpha and apical membrane antigen protein 1 in human erythrocyte-adapted P. knowlesi A1-H.1 strain.

Authors:  Fauzi Muh; Seong-Kyun Lee; Mohammad Rafiul Hoque; Jin-Hee Han; Ji-Hoon Park; Egy Rahman Firdaus; Robert W Moon; Yee Ling Lau; Eun-Taek Han
Journal:  Malar J       Date:  2018-07-27       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.